Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase...

Area of Science:

• Immunology
• Cancer Research
• Cell Therapy

Background:

• Ovarian tumors can evade host immune responses.
• Engineered T cells offer a promising therapeutic strategy.

Purpose of the Study:

• To elucidate the mechanisms by which chimeric NKG2D (chNKG2D) T cells induce host immunity against ovarian tumors.
• To identify the host immune cells critical for tumor elimination following chNKG2D T cell therapy.

Main Methods:

• Treatment of mice with established ovarian tumors using chNKG2D T cells.
• Analysis of cytokine production (IFN-gamma, GM-CSF) in spleen and tumor microenvironment.
• Assessment of tumor antigen presentation and tumor-specific T cell infiltration.
• Evaluation of therapeutic efficacy in genetically modified mice lacking specific immune components (perforin, IFN-gamma, NK cells, T/B cells, GM-CSF, NKT cells).

Main Results:

• chNKG2D T cell treatment sustained increased IFN-gamma production by host NK, CD4(+), and CD8(+) T cells.
• Enhanced tumor antigen presentation and increased tumor-specific T cell numbers were observed at tumor sites and in draining lymph nodes.
• Therapeutic efficacy was dependent on chNKG2D T cell-derived perforin, IFN-gamma, and GM-CSF.
• Host immune mechanisms, including perforin, IFN-gamma, NK cells, and T/B cells, were essential for tumor elimination.
• Host-derived GM-CSF and CD1-dependent NKT cells did not play a significant role.

Conclusions:

• chNKG2D T cells require both cytotoxic and cytokine-secreting functions to stimulate a host antitumor immune response.
• The efficacy of chNKG2D T cell therapy relies on the participation of host immune cells.
• This study highlights the importance of host immune engagement for successful adoptive T cell therapy in ovarian cancer.